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Abstract
Purpose—Insulin-like growth factor (IGF)-I and IGF-II stimulate neoplastic cell growth and
inhibit apoptosis, whereas IGF-binding protein-3 (IGFBP-3) inhibits the bioavailability of IGF-I
and has independent proapoptotic activity. We examined the influence of baseline plasma levels of
IGF-I, IGF-II, IGFBP-3, and C-peptide on outcome among patients receiving first-line
chemotherapy for metastatic colorectal cancer.
Experimental Design—The plasma levels of IGF-I, IGF-II, IGFBP-3, and C-peptide as well as
data on prognostic factors and body size were measured at baseline among 527 patients
participating in a randomized trial of first-line chemotherapy for metastatic colorectal cancer.
Results—Higher baseline plasma IGFBP-3 levels were associated with a significantly greater
chemotherapy response rate (P = 0.03) after adjusting for other prognostic factors, whereas neither
IGF-I nor IGF-II levels significantly predicted tumor response. Higher levels of IGF-I, IGF-II, and
IGFBP-3 were all univariately associated with improved overall survival (P = 0.0001 for all). In a
model that mutually adjusted for IGF-I and IGFBP-3, as well as other prognostic factors,
increasing baseline-circulating IGFBP-3 was associated with a significantly longer time to tumor
progression (P = 0.03), whereas circulating IGF-I was not associated with disease progression (P
= 0.95). Levels of C-peptide were not associated with any measure of patient outcome.
Conclusion—Among colorectal cancer patients receiving first-line chemotherapy, increasing
levels of IGFBP-3, an endogenous antagonist to IGF-I, are associated with an improved objective
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treatment response and a prolonged time to cancer progression. The IGF pathway may represent
an important target for future treatment strategies.
The insulin-like growth factor (IGF) pathway is increasingly recognized for its roles in both
normal growth and development as well as in tumorigenesis. IGF-I, IGF-II, and insulin have
important mitogenic and antiapoptotic properties (1). IGF-I has characteristics of both a
circulating hormone and a tissue growth factor; most IGF-I found in the circulation is
produced by the liver. In laboratory models, inhibition of IGF-I receptor signaling seems to
inhibit cell proliferation and increase the susceptibility of tumor cells to chemotherapeutic
agents (2). Consequently, there has been considerable interest to develop effective targeted
agents that inhibit the IGF-I receptor.
The bioavailability of IGFs is influenced by concentrations of specific IGF-binding proteins
(IGFBP; ref. 1). At least six IGFBPs have been characterized, and their affinity for IGF-I
and IGF-II is in the same order of magnitude as that of the IGF-I receptor. IGFBP-3
provides most of the IGF-binding capacity in serum, and IGFBP-3 is present in the
circulation and in extravascular fluids. By binding to IGF-I, IGFBP-3 can attenuate IGF-I
activity (3). Moreover, there is increasing evidence that the IGFBPs have growth inhibitory
and proapoptotic actions that are independent of their capacity to bind IGFs (4-8). Further
supporting the importance of IGFBP-3 in human colorectal carcinogenesis, a recent
genome-wide survey of human colorectal cancers identified missense mutations in the
IGFBP-3 gene (9).
In prospective studies of healthy subjects, elevated baseline levels of plasma IGF-I (10-16),
IGF-II (16-18), and C-peptide (an indicator of insulin production; refs. 11,14,19-21) are
associated with a greater subsequent risk of developing colorectal cancer, whereas
increasing circulating IGFBP-3 (11-16) is associated with a significant reduction in the risk
of developing colorectal cancer. Few studies have assessed the influence of these circulating
biomarkers on the outcome of patients with established colorectal cancer. Nonetheless,
based on the aforementioned findings, one might hypothesize that, among patients with
newly established colorectal cancer, elevated baseline levels of plasma IGF-I would promote
cancer progression, whereas increased circulating IGFBP-3 would delay or inhibit
subsequent cancer progression.
Translational Relevance
The insulin-like growth factor (IGF) pathway is increasingly recognized for its roles in
normal growth and development as well as in tumorigenesis. In laboratory models,
inhibition of the IGF-I receptor seems to inhibit cell proliferation and increase
susceptibility of tumor cells to chemotherapeutic agents. Consequently, there is a
growing interest in the IGF-I receptor as a potential target for cancer therapy. Among 527
patients participating in a randomized trial of first-line chemotherapy for metastatic
colorectal cancer, we measured baseline plasma levels of IGF-I, IGF-II, IGF-binding
protein-3 (IGFBP-3), and C-peptide. We found that increasing levels of IGFBP-3, an
endogenous antagonist to IGF-I, was associated with an improved objective response to
chemotherapy and a prolonged time to tumor progression.The results of ongoing and
proposed trials of IGF-I receptor antagonists in patients with advanced malignancy will
hopefully provide further insight on the potential role of IGF pathway inhibition in
colorectal cancer therapy.
We therefore examined the influence of pretreatment plasma levels of IGF-I, IGF-II,
IGFBP-3, and C-peptide on cancer progression and survival among patients participating in
a large randomized trial of first-line chemotherapy for metastatic colorectal cancer (N9741;
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ref. 22). By using patients enrolled in a prospective clinical trial with prescribed therapy and
patient follow-up, we could minimize confounding by differences in the use of systemic
chemotherapy, control for other clinical predictors of outcome, and directly examine the
influence of these circulating biomarkers on patient outcome.
Materials and Methods
Patient population
Patients included in this study were drawn from a national, intergroup randomized trial of
chemotherapy for metastatic colorectal cancer (22). Patients were randomized to receive (a)
bolus irinotecan, 5-fluorouracil, and leucovorin; (b) infusional 5-fluorouracil, leucovorin,
and oxaliplatin; or (c) irinotecan and oxaliplatin. Full details of the treatment trial and results
have previously been published (22). Briefly, patients were required to have histologically
proven unresectable colorectal adenocarcinoma, a baseline Eastern Cooperative Oncology
Group performance status of ≤2, and adequate renal, liver, and bone marrow function.
Exclusion criteria included prior therapy for advanced disease, baseline peripheral
neuropathy or central nervous system disease, uncontrolled or severe comorbid illnesses,
and a baseline of >3 loose stools per day. The protocol was reviewed and approved by the
institutional review board of each participating institution. Patients signed informed consent
for participation in the trial and were given the option of inclusion in a companion study of
plasma for future research. In a previous report, we compared the baseline characteristics of
the overall cohort of patients who enrolled in the treatment trial with the subset of patients
participating in the biomarker studies (23). We did not detect any appreciable differences
between these two groups. Further, patients experienced similar overall survival, with a
median survival of 18.1 mo among all patients enrolled in the clinical trial and 18.2 mo
among the patients who provided blood samples for plasma biomarkers.
Response and progression criteria
Study enrollment required at least one measurable lesion (≥2 cm in diameter) or disease that
could be serially evaluated to establish whether the disease was getting better or worse
(evaluable disease). Objective response to chemotherapy was calculated among patients with
measurable disease (n = 474), whereas time to progression and overall survival were
assessed among all study subjects (N = 527). Complete response required ≥50% reduction in
the sum of the products of the longest perpendicular diameters of all measurable lesions.
Regression required documented tumor reduction in evaluable patients who did not have
disease that met the guidelines for measurable disease. Disease progression required ≥25%
increase in measurable tumor or an increase in tumor size in patients whose lesions did not
meet the criteria for measurable disease. After partial response, tumor measurements >50%
of the maximal extent of a previously observed reduction constituted progression. Any new
lesion constituted progression. Patients who did not meet the definitions of response or
progression were classified as having stable disease.
Time to progression was calculated from study entry to disease progression, regardless of
the patient’s treatment status. Deaths occurring within 30 d of treatment discontinuation
were considered progressions. Survival was calculated from enrollment to death or last
contact. Without contradictory data, patients who died or were lost to follow-up were
assumed to have progressed at the time they were last documented to be progression-free.
Plasma biomarker measurement
Blood samples were collected upon study registration at the respective institutions and sent
to the Mayo Central Laboratory for Clinical Trials in Rochester, Minnesota. Whole-blood
samples were cooled and sent by overnight delivery to the laboratory. The stability of these
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biomarkers during the period of transport has been previously documented (24). Samples
were centrifuged, divided, and frozen before use. IGF-I, IGF-II, IGFBP-3, and C-peptide
levels were assayed in the laboratory of Dr. Michael Pollak, using enzyme-linked
immunosorbent assays with reagents provided by Diagnostic Systems Laboratory. All assays
were carried out by laboratory personnel who were blinded to patient outcome. Each sample
was assayed in duplicate for each analyte, and correlations between replicates were >0.95. In
previous studies, the mean intrabatch coefficients of variation calculated from the quality-
control samples were 7%, 5%, 9%, and 10% for IGF-I, IGF-II, IGFBP-3 and C-peptide,
respectively (11,15,25,26).
Statistical analysis
In total, 1,379 patients were enrolled in N9741 after the incorporation of an amendment to
collect blood samples for companion biomarker studies. Of this cohort, 527 patients
provided blood samples for these analyses. Plasma biomarkers were each categorized
according to quartiles. To assess the relation between the various plasma biomarkers and
confirmed response rate to chemotherapy, linear tests for trend using multivariate logistic
regression were conducted with each plasma biomarker modeled continuously in a model
that included other potential predictors of patient outcome. The Kaplan-Meier method was
used to describe the distribution of time to disease progression and overall survival time
(27). Cox proportional hazards modeling was used to calculate hazard ratios and confidence
intervals (28). In secondary analyses, we assessed the joint effects of plasma IGF-I and
IGFBP-3 levels on patient outcome; to provide increased power for these cross-stratified
subgroup analyses, plasma IGF-I and IGFBP-3 levels were categorized into tertiles only for
these joint effect analyses. Tests for trend using two-sided P values were calculated by
entering values for a specific biomarker as a continuous variable into the multivariate model.
To satisfy the normality assumption, C-peptide was log-transformed when modeling. All
statistical analyses used the SAS program package version 8.02 (SAS Institute). Two sided
P values <0.05 were used to denote statistical significance.
Results
Patient characteristics
Among the 527 patients who provided baseline plasma samples for analysis, we examined
baseline patient characteristics according to quartiles of plasma IGF-I and IGFBP-3 (Table
1). Participants on the highest level of IGF-I and IGFBP-3 were younger, possessed a higher
body mass index (BMI), and were less likely to possess an Eastern Cooperative Oncology
Group performance status of 2. Compared with the lowest categories, participants in the
highest quartile of IGF-I were more often male, whereas those in the highest category of
IGFBP-3 were more often female.
Correlations between plasma markers, body mass index and performance status
We examined the relations among IGF axis biomarkers, C-peptide, BMI, and baseline
performance status (Table 2). We defined correlation coefficients of >0.6 as strong, between
0.3 and 0.6 as moderate, and <0.3 as weak or nonexistent (29). Using Spearman correlations,
we found strong correlations among IGF-I, IGF-II, and IGFBP-3 but weaker correlations for
these proteins and either C-peptide, BMI, or performance status. Neither C-peptide nor BMI
was associated with baseline performance status.
Plasma biomarkers levels and tumor response
We examined the influence of baseline plasma biomarker levels on the subsequent rates of
objective response to systemic chemotherapy. Baseline levels of plasma IGF-I, IGF-II, and
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C-peptide were not significantly associated with objective tumor response (P = 0.59, 0.60,
and 0.33, respectively). However, increasing baseline IGFBP-3 levels were associated with
significantly higher rates of tumor response (multivariate P for trend = 0.03), after adjusting
for age, gender, performance status, BMI, and treatment arm (Fig. 1). The response rate was
35% for individuals in the lowest quartile of IGFBP-3 compared with 53% in the highest
quartile.
Plasma biomarkers and patient outcome
We also examined the influence of baseline plasma biomarkers on time to progression and
overall survival (Table 3). Higher baseline levels of IGF-I, IGF-II, and IGFBP-3 were each
associated with significantly lower risks of disease progression and death, after adjusting for
other patient characteristics. In contrast, levels of C-peptide were not predictive of either
time to progression or mortality. Of note, the effect of IGF-I, IGF-II, and IGFBP-3 on
patient outcome did not differ significantly according to treatment arm, age, gender, or BMI
(data not shown).
Because participants in the lowest categories of IGF-I, IGF-II, and IGFBP-3 tended to
possess a lower BMI and worse performance status, we considered the possibility that the
relation between these plasma biomarkers and patient outcome could simply reflect the
influence of either an impaired patient nutritional or performance status. Therefore, beyond
the aforementioned multivariate models, we repeated our analyses after excluding
participants with a BMI <23 kg/m2 or an Eastern Cooperative Oncology Group performance
status of 2. Among the 426 patients remaining after these exclusions, higher baseline levels
of IGF-I, IGF-II, and IGFBP-3 each remained associated with significantly lower risks of
disease progression (P for trend = 0.01, 0.0005, and 0.003, respectively) and death (P for
trend < 0.0001 for all three biomarkers).
To assess the independent effects of circulating IGF-I and IGFBP-3, we mutually adjusted
for plasma levels of both IGF-I and IGFBP-3 in our multivariate model (Table 4). Within
the limitations of mutually adjusting for correlated biomarkers (30), higher circulating levels
of IGF-I and IGFBP-3 were each associated with a declining mortality risk, although neither
association with overall survival reached statistical significance (P for trend = 0.12 and 0.07
for IGF-I and IGFBP-3, respectively). In contrast, when we mutually adjusted for IGF-I and
IGFBP-3, increasing circulating IGFBP-3 was associated with a significant improvement in
time to progression (P for trend = 0.03), whereas levels of IGF-I were not associated with
the risk of disease progression (P for trend = 0.95).
Finally, in exploratory analyses, we examined the joint effects of plasma IGF-I and IGFBP-3
levels on tumor response and the risk of tumor progression (Table 5). To provide increased
power for these cross-stratified analyses, plasma IGF-I and IGFBP-3 levels were categorized
into tertiles. As IGF-I and IGFBP-3 levels are strongly correlated (as shown in Table 2), the
general distribution of subjects in Table 5 showed a relatively small number of subjects in
the cells where IGF-I levels and IGFBP-3 levels were discordant. In contrast, most subjects
appeared in the three cells where IGF-I and IGFBP-3 were in the same tertile. Interestingly,
the relatively small number of “outlier” individuals found to simultaneously be in the
highest tertile of IGF-I and the lowest tertile of IGFBP-3 seemed to experience the lowest
response rate (17%) and the highest risk of tumor progression (hazard ratio, 2.65; 95%
confidence interval, 1.07-6.56). In contrast, patients in the middle tertile of IGF-I and the
highest tertile of IGFBP-3 seemed to experience the lowest risks of tumor progression
(hazard ratio, 0.59; 95% confidence interval, 0.41-0.85).
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In this cohort of patients with previously untreated metastatic colorectal cancer, higher
baseline circulating levels of IGFBP-3 were associated with a significantly greater response
rate to chemotherapy and a longer time to tumor progression and overall survival, even after
adjusting for other potential predictors of patient outcome. Of note, higher baseline plasma
levels of IGF-I and IGF-II also predicted longer times to tumor progression and overall
survival, although neither factor was significantly associated with chemotherapy response
rate. Moreover, when we mutually adjusted for IGF-I and IGFBP-3, only IGFBP-3 remained
a significant predictor of tumor progression. Finally, baseline levels of C-peptide, a marker
of circulating insulin, were not associated with any measure of treatment efficacy or patient
survival.
The significant influence of higher baseline circulating levels of IGFBP-3 on chemotherapy
response rate, time to progression, and survival bears interest. In the only other study of
circulating IGFs in colorectal cancer patients, higher IGFBP-3 was similarly associated with
a 48% reduction in colorectal cancer – specific mortality whereas IGF-I was not associated
with patient outcome (31). IGFBP-3 induces apoptosis using both IGF-dependent and IGF-
independent mechanisms (4-8,32). In murine model systems, IGFBP-3 seems to act through
IGF-I–dependent mechanisms early in cancer development; however, during the later stages
of tumorigenesis, when angiogenesis, invasion, and inhibiting apoptosis are critical for the
tumor, IGFBP-3 seems to act as a tumor suppressor entirely through an IGF-independent
mechanism (33). Moreover, supporting the importance of IGFBP-3 in human colorectal
carcinogenesis, a recent genome-wide survey of human colorectal cancers identified
missense mutations in the IGFBP-3 gene (9).
In preclinical models, overexpression of IGFBP-3 conferred significant tumor reduction
with only minimal effects on normal tissues (33). Moreover, in a previous analysis of this
cohort, baseline circulating IGFBP-3 was not associated with baseline quality of life
measures despite the significant benefit of IGFBP-3 levels on subsequent chemotherapy
response and tumor progression (23). The possibility that IGFBP-3 inhibits tumor growth,
with minimal apparent deleterious effects on normal host functions, represents an attractive
feature in the development of IGFBP-3 as an anticancer agent (33).
We hypothesized that, among patients with newly established colorectal cancer, elevated
baseline levels of plasma IGF-I would promote cancer progression, whereas increased
circulating IGFBP-3 would delay or inhibit subsequent cancer progression. Although
elevated baseline IGFBP-3 did predict a greater response rate to chemotherapy and a longer
time to tumor progression and overall survival, the improved overall survival associated
with higher circulating levels of IGF-I and IGF-II in this cohort seems counterintuitive,
given the presumed tumor-promoting properties of these molecules. The levels of IGF-I,
IGF-II, and C-peptide are influenced by malnutrition (1,34,35). As such, the inferior survival
of patients with reduced levels of IGF-I and IGF-II could have reflected impaired nutritional
status and/or impaired patient performance status secondary to a greater cancer burden.
However, our findings remained significant after controlling BMI and performance status,
and our results did not change after excluding leaner patients and those with an impaired
performance status. Moreover, although C-peptide has also been associated with nutritional
status (36,37), levels of C-peptide were not predictive of patient survival in this cohort.
Alternatively, IGF-I and IGF-II may play an essential role in maintaining the functional
capacity of the “host” (38,39). In addition to their role in modulating the balance between
cellular proliferation and apoptosis, the IGFs play key roles in regulating energy
metabolism, body size, and various organspecific functions (1,34,35). Indirect support of
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this hypothesis is seen in patients with growth hormone deficiency treated with growth
hormone replacement, in which IGF-I levels increase and the quality of life improves
(40,41). Administration of recombinant IGF-I in selected chronic diseases improved quality
of life in some studies (42), but not others (43,44). Notably, in a previous analysis of this
cohort of colorectal cancer patients (23), higher baseline levels of IGF-I and IGF-II were
both associated with a superior quality of life and diminished symptom distress. In contrast,
C-peptide was not associated with quality of life measures (23), consistent with the failure of
C-peptide to predict survival in the current analysis.
We acknowledge that this study has several limitations. Although baseline BMI was
recorded in this trial, we did not collect information on weight loss that may have occurred
immediately before study enrollment. Thus, residual confounding by cachexia secondary to
advanced malignancy cannot be excluded. Nonetheless, in contrast to IGF-I, IGF-II, and C-
peptide, levels of IGFBP-3 seem to be less influenced by nutritional factors (33). In addition,
baseline protein levels may be influenced by morbidity from recent surgery or burden of
cancer; however, our findings remained unchanged after adjusting for performance status
and BMI and after exclusion of leaner patients with an impaired performance status.
Moreover, as part of the clinical trial, all patients were required to have adequate
biochemical parameters and performance status for enrollment, and >90% of study subjects
had an Eastern Cooperative Oncology Group performance status of 0 or 1. In addition,
because chemotherapy was defined by the clinical trial, residual confounding by choice of
chemotherapy was minimized.
Although patients with poorly controlled diabetes mellitus or hyperglycemia were excluded
from the trial, patients with adequately controlled diabetes mellitus were eligible. The
clinical trial did not collect data on history of diabetes mellitus; nonetheless, previous
studies have shown that circulating levels of IGF-I or IGFBP-3 are not materially influenced
by abnormalities such as glucose intolerance or diabetes mellitus (45). Moreover, as shown
in the analysis, plasma C-peptide, which is clearly influenced by glucose homeostasis, was
not associated with chemotherapy response rate, time to progression, or overall survival
among these 527 patients with metastatic colorectal cancer.
Plasma biomarker levels were only measured at the start of chemotherapy, and the effect of
changes in the levels of these growth factors on patient outcome could not be assessed.
However, one study of women receiving chemotherapy for advanced breast cancer showed
that IGF-I did not change on therapy, whereas IGFBP-3 only modestly decreased (46).
Additionally, our study sought to examine the influence of baseline plasma factors on
patient prognosis and was not adequately powered to examine the predictive value of these
markers with respect to specific chemotherapies. Nonetheless, we did not detect any
significant interaction between IGF-I, IGF-II, or IGFBP-3 and chemotherapy treatment
assignment in our analysis.
There is a growing interest in the IGF pathway as a potential target for cancer therapy
(1,2,47). Among colorectal cancer patients receiving front-line chemotherapy, our data
suggest that increasing levels of an endogenous antagonist to IGF-I, IGFBP-3, may
substantially improve objective treatment response and delay cancer progression. However,
our results also suggest that a minimum level of circulating IGF-I may be needed to
maintain the functional capacity and/or survival of the host. The results of ongoing and
proposed trials of IGF-I receptor antagonists in patients with advanced malignancy will
hopefully provide further insight in the potential role of IGF pathway inhibition in cancer
therapy.
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